Pryor Cashman represented Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460) in the acquisition by the Group’s wholly-owned subsidiary, Xuanzhu (HK) Biopharmaceutical Limited, of all rights and intellectual property for Plazomicin for Greater China. Plazomicin, which is administrated by intravenous (IV) infusion, is an aminoglycoside antibiotic approved by the U.S. Food and Drug Administration for the treatment of complicated urinary tract infections.
The Pryor Cashman team was composed of partners Jeffrey Johnson, Rich Levy, Jr., and Rich Frazer, with the assistance of partner Lawrence Remmel, and associate Vedad Tabich. Secondee Joy Baur also assisted in the deal.
About Sihuan Pharmaceuticals
Sihuan Pharmaceutical Holdings Group Ltd. is a pharmaceutical group with integrated R&D, production and sales capabilities that offers a nationwide sales network in China and a diversified product portfolio. The Group’s current products and R&D pipeline include cardiovascular, central nervous, metabolism, oncology, and diabetes products, which are the top five medical therapeutic areas in China.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.